Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02520609 · ClinicalTrials.gov registry record
Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease
A clinical trial of Fatty Liver and Liver Disease, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- 53
- Enrollment target
- 1
- Study location
NCT02520609: Completed study of Fatty Liver and Liver Disease, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
NCT02520609 is a study of Fatty Liver and Liver Disease that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 53 participants, below the 208-participant average among 20 other Fatty Liver trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02520609, a study of Fatty Liver and Liver Disease, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- 53 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Metabolism refers to the many chemical pathways by which various compounds, including food, are processed and used in the body. People with non-alcoholic fatty liver disease (NAFLD) have too much fat in their liver cells, but what causes it is unclear. One explanation is that people with NAFLD process food and metabolize it differently than people without NAFLD. Researchers want to compare how food is metabolized in people with and without NAFLD. Objective: To better understand how food intake influences the development and progression of NAFLD. Eligibility: People ages 18 and older with NAFLD or with a non-NAFLD metabolic syndrome Healthy volunteers ages 18 and older Design: Participants will be screened with medical history, surveys, physical exam, and blood tests. This will have ultrasound of the abdomen. This uses sound waves to image internal organs. Participants will stay at the Clinical Center for 2 nights. They will fast he first night. On the second day they will: Have their metabolism monitored in a metabolism research room for 24 hours Have a catheter inserted into an arm vein for several blood tests Drink an Ensure Plus for breakfast Have solid meals for lunch and dinner Have several urine tests. The final morning, they will: Have more blood tests. Have a DXA test to measure the fat in the body. They will lie on their backs for 15-25 minutes while an x-ray machine is positioned over areas of the body.
Primary Outcome
Plasma metabolomic Readout
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2015-10-28 |
| Est. Completion | 2020-05-14 |
What the finished NCT02520609 record still lists
NCT02520609 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 208-participant average among 20 other Fatty Liver trials with a reported enrollment target (75% lower).
The record links to 2 conditions, with Fatty Liver appearing as the primary indexed condition, and to 0 interventions.
NCT02520609 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT02520609 about?
NCT02520609 is a clinical study titled "Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease". Background: Metabolism refers to the many chemical pathways by which various compounds, including food, are processed and used in the body. People with non-alcoholic fatty liver disease (NAFLD) have too much fat in their liver cells, but what causes it is unclear. One explanation is that people wit...
What is the current status of trial NCT02520609?
This trial is currently completed. The enrollment target is 53 participants. The study started on 2015-10-28. Estimated completion is 2020-05-14.
What conditions does trial NCT02520609 study?
This clinical trial studies the following conditions: Fatty Liver, Liver Disease.
Who is sponsoring clinical trial NCT02520609?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02520609 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fatty Liver
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02520609's enrollment target sits among peer trials
53 12th of 20 higher than 9 of 20 other Fatty Liver trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Fatty Liver trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intermittent Fasting for NAFLD in Adults
RECRUITING · NA
-
Early Tracking of Childhood Health Determinants (ETCHED) Study
RECRUITING
-
Exploratory Analysis of Enhanced Liver Function (ELF) Test to Detect Early Fatty Liver in High Risk Population
RECRUITING
-
Blood Collection Biorepository for Liver Disease Research
RECRUITING
-
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
ACTIVE NOT RECRUITING · Phase 2
-
Liver Positron Emission Tomography (PET) Study of Non Alcoholic Fatty Liver Disease
COMPLETED · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI